Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency

Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs. (C) 2021 Societe francaise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Automated summary

Pathogen reduction technologies (PRT) are recommended by regulatory authorities to reduce the risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. However, there is theoretical concern that PRT may impact the efficacy of convalescent plasma by altering neutralizing antibodies. Evidence suggests that PRT does not have a significant detrimental effect on neutralizing antibodies.